High-Dose Lovastatin for Acute Ischemic Stroke: Results of the Phase I Dose Escalation Neuroprotection with Statin Therapy for Acute Recovery Trial (NeuSTART)

Abstract

Lovastatin at doses above those currently approved by the Food and Drug Administration is feasible for 3 days after an acute ischemic stroke and the maximum tolerated dose is estimated to be 8 mg/kg/day. Further randomized studies are warranted to confirm its safety and to demonstrate its efficacy in improving functional outcomes after stroke.

References

Page 1

	Year	Citations
High-Dose Atorvastatin after Stroke or Transient Ischemic Attack New England Journal of Medicine	2006	2.9K
Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer John O’Quigley, Margaret S. Pepe, Lloyd D. Fisher Biometrics Cancer ManagementClinical EndpointDose Toxicity CurveOncologyClinical Trials	1990	1.6K
Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase Matthias Endres, Ulrich Laufs, Zhihong Huang, Proceedings of the National Academy of Sciences	1998	969
The statins as anticancer agents. Kelvin Chan, Amit M. Oza, Lillian L. Siu PubMed Chemoprevention StrategyPharmacotherapyAnticancer AgentsTumor BiologyInflammation	2003	604
Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomised controlled pilot trial James Kennedy, Michael D. Hill, Karla J. Ryckborst, The Lancet Neurology Cerebrovascular DiseaseThrombosisStroke RehabilitationStrokeNeurology	2007	552
Statins induce angiogenesis, neurogenesis, and synaptogenesis after stroke Jieli Chen, Zheng Gang Zhang, Yi Li, Annals of Neurology Cerebral Vascular RegulationThrombosisAngiogenesisStrokeNeurology	2003	535
Sequential Designs for Phase I Clinical Trials with Late‐Onset Toxicities Ying Kuen Cheung, Rick Chappell Biometrics Clinical EndpointSmall GroupTranslational MedicineSequential DesignsTraditional Designs	2000	521
Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer. Alain Thibault, Dvorit Samid, A Tompkins, PubMed OncologyMedicineMevalonate PathwayPathologyTransient Inhibitory Activity	1996	361
Statin treatment withdrawal in ischemic stroke M. Blanco, Florentino Nombela, Mar Castellanos, Neurology	2007	327
Mevastatin, an HMG-CoA Reductase Inhibitor, Reduces Stroke Damage and Upregulates Endothelial Nitric Oxide Synthase in Mice Sepideh Amin‐Hanjani, Nancy E. Stagliano, Masaru Yamada, Stroke	2001	326

Page 1